跳至主要内容
临床试验/DRKS00011205
DRKS00011205招募中不适用

Cellular immunity after alemtuzumab - ZINA

niversitätsklinikum Köln0 个研究点目标入组 20 人开始时间: 2017年2月21日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 99 Years(—)
性别
All

入选标准

  • Multiple Sclerosis patients starting therapy with alemtuzumab

排除标准

  • revocation of consent and underage patients

研究者

发起方
niversitätsklinikum Köln

相似试验

招募中
不适用
Impact of alemtuzumab exposure on immune reconstitution, autoimmunity, risk of infection, chimerism and graft-versus-host disease in children with non-malignant diseases undergoing allogeneic stem celltransplantation - an International Multicenter Observational Study.
NL-OMON22218eiden University Medical Center30
进行中(未招募)
1 期
Alemtuzumab and rheumatoid arthritis - a study to look at the function of the immune systemMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid Arthritis
EUCTR2010-021146-22-GBThe Newcastle upon Tyne Hospitals NHS Foundation Trust17
已完成
不适用
Impact of Alemtuzumab exposure on immune reconstitution, autoimmunity, risk of infection, chimerism and Graft-versus-Host Disease in children with non-malignant diseases undergoing allogeneic stem cell transplantation. ARTIC International Multicenter Observational Study.Group of inherited blood diseases that affect red blood cells (e.g. sickle cell diseasethalassemia) and/or white blood cells (e.g. severe combined immunodeficiency characterized by a profound reduction or absence of T lymphocyte function) requiring an allogeneic stem cell transplantation.100189021002142910021460
NL-OMON55607eids Universitair Medisch Centrum7
招募中
4 期
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective PotentialG35.10
DRKS00007777niversitätsklinikum Münster, Dr. Christoph Hoppenheit15
进行中(未招募)
1 期
Investigation on how alemtuzumab acts in patients with relapsing remitting multiple sclerosis.
EUCTR2014-000709-10-DEniversitätsklinikum Münster15